Estrella Immunopharma, Inc.

ESLA Nasdaq SEC CIK 1844417
Follow Estrella Immunopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7.4M −53.8% vs same quarter last year
EPS, diluted −$0.17 −30.8% vs same quarter last year
Operating cash flow −$217.2K +70.1% vs same quarter last year
Operating income −$7.5M −58.3% vs same quarter last year
Net income by quarter
−$3.4M
−$2.1M
−$5.5M
−$4.8M
−$613.2K
−$2.3M
−$2.3M
−$7.4M
Q3 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$15M−$10M−$5M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$13.1M
FY24−$7.3M
FY23−$11.1M
FY22−$996.1K
FY21−$247.7K
FY20-